DNA Biomed Solns Cash Flow Conversion Efficiency

Latest as of June 2023: -0.003x

DNA Biomed Solns cash flow conversion efficiency. Based on the latest financial reports, DNA Biomed Solns (DNA) has a cash flow conversion efficiency ratio of -0.003x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-265.00K ≈ $-710.46 USD) by net assets (ILA82.79 Million ≈ $221.96K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of DNA Biomed Solns (2013–2024)

Cash flow conversion efficiency of DNA Biomed Solns from 2013 to 2024. This chart illustrates how DNA Biomed Solns's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for DNA Biomed Solns for real-time trading data and today's change.

DNA Biomed Solns Cash Flow Conversion Ratio Explained

DNA Biomed Solns cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

DNA Biomed Solns Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of DNA Biomed Solns ranked by their cash flow conversion efficiency. Also see DNA Biomed Solns market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Harvard Bioscience Inc NASDAQ:HBIO	0.044x
Park Elektrik Uretim Madencilik Sanayi ve Ticaret AS IS:PRKME	0.001x
Jaba I Inversiones Inmobiliarias Socimi SA MC:YABA	0.001x
Viscount Mining Corp. V:VML	-0.052x
Hana Must SPAC 2 KQ:208370	0.013x
Logistea A ST:LOGI-A	0.020x
Herantis Pharma Oyj HE:HRTIS	-1.937x
Samkee Automotive Co. Ltd KQ:122350	0.044x

Annual Cash Flow Conversion Efficiency for DNA Biomed Solns (2013–2024)

The table below shows the annual cash flow conversion efficiency of DNA Biomed Solns from 2013 to 2024. Review DNA Biomed Solns free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	ILA101.47 Million ≈ $272.02K	ILA1.61 Million ≈ $4.32K	0.016x	+285.32%
2023-12-31	ILA79.19 Million ≈ $212.30K	ILA-678.00K ≈ $-1.82K	-0.009x	-93.75%
2022-12-31	ILA80.11 Million ≈ $214.76K	ILA-354.00K ≈ $-949.06	-0.004x	+89.70%
2021-12-31	ILA54.33 Million ≈ $145.66K	ILA-2.33 Million ≈ $-6.25K	-0.043x	+44.17%
2020-12-31	ILA7.95 Million ≈ $21.32K	ILA-611.00K ≈ $-1.64K	-0.077x	-57.74%
2019-12-31	ILA28.18 Million ≈ $75.56K	ILA-1.37 Million ≈ $-3.68K	-0.049x	-90.35%
2018-12-31	ILA64.90 Million ≈ $174.00K	ILA-1.66 Million ≈ $-4.45K	-0.026x	+7.16%
2017-12-31	ILA69.11 Million ≈ $185.27K	ILA-1.91 Million ≈ $-5.11K	-0.028x	-116.08%
2016-12-31	ILA-83.41 Million ≈ $-223.63K	ILA-14.30 Million ≈ $-38.34K	0.171x	-90.81%
2015-12-31	ILA-8.35 Million ≈ $-22.38K	ILA-15.57 Million ≈ $-41.73K	1.865x	+41.84%
2014-12-31	ILA-8.36 Million ≈ $-22.40K	ILA-10.99 Million ≈ $-29.45K	1.315x	+391.99%
2013-12-31	ILA11.49 Million ≈ $30.80K	ILA-5.17 Million ≈ $-13.87K	-0.450x	--

About DNA Biomed Solns

TA:DNA Israel Biotechnology

Market Cap

$36.55 Million

ILA13.63 Billion ILA

Market Cap Rank

#22850 Global

#314 in Israel

Share Price

ILA110.70

Change (1 day)

-0.81%

52-Week Range

ILA86.00 - ILA145.00

All Time High

ILA1900.80